Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKAN NASDAQ:ENTO NASDAQ:IMNN NASDAQ:VBIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$12.33$19.51$2.30▼$209.02$6.67M14.06313,048 shs20,408 shsENTOEntero Therapeutics$4.40-1.1%$4.36$0.32▼$5.84$6.99M1.192.80 million shs42,196 shsIMNNImunon$1.91$2.22$1.70▼$10.69$8.03M1.9671,057 shs31,829 shsVBIVVBI Vaccines$0.07$0.23$0.06▼$1.35$1.87M2.183.66 million shsN/A7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%-11.64%-25.23%+298.20%-86.51%ENTOEntero Therapeutics-1.12%+1.62%-31.99%+84.10%+262.14%IMNNImunon0.00%+6.70%-9.05%-40.68%-84.08%VBIVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$12.33$19.51$2.30▼$209.02$6.67M14.06313,048 shs20,408 shsENTOEntero Therapeutics$4.40-1.1%$4.36$0.32▼$5.84$6.99M1.192.80 million shs42,196 shsIMNNImunon$1.91$2.22$1.70▼$10.69$8.03M1.9671,057 shs31,829 shsVBIVVBI Vaccines$0.07$0.23$0.06▼$1.35$1.87M2.183.66 million shsN/A7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda0.00%-11.64%-25.23%+298.20%-86.51%ENTOEntero Therapeutics-1.12%+1.62%-31.99%+84.10%+262.14%IMNNImunon0.00%+6.70%-9.05%-40.68%-84.08%VBIVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 1.00SellN/AN/AENTOEntero Therapeutics 1.00SellN/AN/AIMNNImunon 2.00Hold$10.00423.56% UpsideVBIVVBI Vaccines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VBIV, IMNN, ENTO, and AKAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$10.004/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/10/2026AKANAkanda Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$260K25.61N/AN/A($25.68) per share-0.48ENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/AIMNNImunonN/AN/AN/AN/A$2.30 per shareN/AVBIVVBI Vaccines$9.41M0.20N/AN/A$0.32 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$45.65MN/AN/AN/AN/AN/AN/AN/AN/AENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%N/AIMNNImunon-$14.49M-$5.16N/AN/AN/AN/A-341.23%-153.79%8/4/2026 (Estimated)VBIVVBI Vaccines-$92.84MN/AN/AN/AN/A-881.79%-525.42%-45.87%N/ALatest VBIV, IMNN, ENTO, and AKAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/9/2026Q4 2025AKANAkandaN/A-$317.9020N/A-$317.9020N/AN/A5/12/2026Q1 2026IMNNImunon-$1.2150-$0.84+$0.3750-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A0.580.58ENTOEntero TherapeuticsN/A2.622.62IMNNImunonN/A1.591.59VBIVVBI VaccinesN/A0.340.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%ENTOEntero Therapeutics12.30%IMNNImunon4.47%VBIVVBI Vaccines12.26%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%ENTOEntero Therapeutics0.75%IMNNImunon2.83%VBIVVBI Vaccines10.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda110540,000431,000Not OptionableENTOEntero Therapeutics91.59 million3.34 millionN/AIMNNImunon304.20 million4.08 millionNot OptionableVBIVVBI Vaccines2228.68 million25.71 millionNo DataVBIV, IMNN, ENTO, and AKAN HeadlinesRecent News About These CompaniesBrii Biosciences buying VBI Vaccine’s hepatitis B therapyJanuary 24, 2025 | ncbiotech.orgNVBI Vaccines Restructures and Acquired by K2 VBI TrustJanuary 3, 2025 | tipranks.comVBI recalls PreHevbrio and winds down operationsNovember 20, 2024 | thepharmaletter.comTHepatitis B Vaccine PreHevbrio Recalled Due to Company BankruptcyNovember 19, 2024 | empr.comEVBI Vaccines recalls hepatitis B shot as it winds down operationsNovember 18, 2024 | fiercepharma.comFVBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company OperationsNovember 15, 2024 | businesswire.comVBI Vaccines Inc. (VBIV): Unpacking the 80% Stock Surge During RestructuringAugust 6, 2024 | bovnews.comBWhy Is VBI Vaccines (VBIV) Stock Up 62% Today?August 6, 2024 | investorplace.comVBI Vaccines to be delisted from Nasdaq following restructuringAugust 4, 2024 | investing.comVBI Vaccines Provides an Update on its Restructuring ProceedingsAugust 3, 2024 | finance.yahoo.comVBI Vaccines secures court protection for restructuringAugust 1, 2024 | investing.comVBI craters as investors react to Hep B vaccine dataJuly 31, 2024 | pharmaphorum.comPVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesJuly 30, 2024 | stockhouse.comVBI Vaccines Announces Results of Annual General MeetingJune 25, 2024 | businesswire.comVBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma PatientsMay 29, 2024 | businesswire.comVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma PatientsMay 22, 2024 | businesswire.comVBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | investorplace.comVBI Vaccines Reports First Quarter 2024 Financial ResultsMay 15, 2024 | businesswire.comVBI Vaccines expands partnership with Canadian government on a vaccine platformMay 13, 2024 | plant.caPVBI Vaccines Reports Full Year 2023 Financial ResultsApril 16, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVBIV, IMNN, ENTO, and AKAN Company DescriptionsAkanda NASDAQ:AKAN$12.33 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$12.80 +0.48 (+3.85%) As of 07/2/2026 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Entero Therapeutics NASDAQ:ENTO$4.40 -0.05 (-1.12%) As of 07/2/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Imunon NASDAQ:IMNN$1.91 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.98 +0.07 (+3.61%) As of 07/2/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.VBI Vaccines NASDAQ:VBIVVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
